Rebecca B. Robertson Sells 7,445 Shares of CeriBell, Inc. (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) Director Rebecca B. Robertson sold 7,445 shares of the company’s stock in a transaction dated Tuesday, June 17th. The shares were sold at an average price of $17.63, for a total transaction of $131,255.35. Following the completion of the transaction, the director now directly owns 21,230 shares of the company’s stock, valued at approximately $374,284.90. The trade was a 25.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

CeriBell Stock Performance

Shares of CeriBell stock opened at $17.91 on Friday. The firm’s 50-day simple moving average is $16.67 and its 200-day simple moving average is $20.69. The company has a debt-to-equity ratio of 0.11, a quick ratio of 16.81 and a current ratio of 17.36. CeriBell, Inc. has a 1 year low of $10.01 and a 1 year high of $32.75.

CeriBell (NASDAQ:CBLL) last issued its earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.07. The company had revenue of $20.49 million during the quarter, compared to analyst estimates of $19.30 million. Equities research analysts forecast that CeriBell, Inc. will post -2.46 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have weighed in on CBLL. Canaccord Genuity Group reissued a “buy” rating and issued a $33.00 price objective on shares of CeriBell in a research report on Wednesday, February 26th. LADENBURG THALM/SH SH began coverage on shares of CeriBell in a research report on Friday, April 4th. They issued a “buy” rating and a $32.00 price objective for the company. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $32.50.

Institutional Investors Weigh In On CeriBell

Institutional investors have recently modified their holdings of the stock. Rhumbline Advisers acquired a new stake in CeriBell during the fourth quarter worth about $320,000. Ameriprise Financial Inc. acquired a new stake in CeriBell during the fourth quarter worth about $368,000. Corebridge Financial Inc. acquired a new stake in CeriBell during the fourth quarter worth about $158,000. PNC Financial Services Group Inc. acquired a new stake in CeriBell during the fourth quarter worth about $47,000. Finally, Bank of America Corp DE acquired a new stake in CeriBell during the fourth quarter worth about $498,000.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.